跳至主要内容
临床试验/ACTRN12622000446763
ACTRN12622000446763撤回1 期

A single dose, randomised, 2-period, 2-sequence, crossover, relative bioavailability study comparing 1 x 60 mg R-192 tablet with 1 x 60 mg R-107 tablet administered orally in healthy participants under fasting conditions.

Zenith Technology Corporation Limited0 个研究点目标入组 14 人开始时间: 2022年3月21日最近更新:
适应症

试验速览

阶段
1 期
状态
撤回
入组人数
14

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 55 Years(—)
性别
All

入选标准

  • Healthy participants.
  • Aged between 18 and 55
  • Non-smoker
  • BMI between 18.5 and 30
  • Healthy individuals in good health as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
  • The absence of mental illness requiring medication or treatment by a physician.
  • Able to provide written informed consent

排除标准

  • Concomitant drug therapy of any kind
  • Any history of mental illness requiring medication or treatment by a physician.
  • Receiving treatment with monoamine oxidase inhibitors, vasoconstriction agents, thyroxine or benzodiazepines.
  • History of significant drug abuse or dependency including R-107 or its excipients within one year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 year prior to screening.
  • Significant current risk of suicide as assessed by eC-SSRS, or serious risk for suicide, as assessed by the evaluating study clinician.
  • Sensitive to the study drug
  • History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
  • Participants of child- bearing potential who are pregnant and/or breastfeeding
  • Smoker (anyone who has smoked in the last 6 months)
  • History of alcohol abuse or dependency
  • Participation in a drug study within 60 days of the start of the study or donated blood within the 60 days preceding the study
  • Volunteers for whom the Clinical Investigator believer, for any reason, that participation would not be an acceptable risk

研究者

相似试验

撤回
1 期
Comparative bioavailability assessment between 2 x 10 mg R-178 tablets and 2 x 10 mg 2-amino-1,7-dihydro-6H-purine-6-thione tablets administered orally in healthy participants under fasting conditions.2-amino-1,7-dihydro-6H-purine-6-thione is indicated for the maintenance treatment of inflammatory bowel disease (Crohn's disease or ulcerative colitis).Oral and Gastrointestinal - Crohn's diseaseOral and Gastrointestinal - Inflammatory bowel disease
ACTRN12622000579796Zenith Technology Corporation Limited14
撤回
1 期
Comparative bioavailability assessment between 4 x 60 mg R107 tablets administered orally and 0.5mg/kg ketamine IV infusion over 40 minutes in healthy male and female participants under fasting conditions.Mental Health - DepressionMental Health - AnxietyDepressionAnxiety
ACTRN12618001135202Zenith Technology Corporation Limited12
撤回
1 期
Comparative bioavailability assessment between R107 tablet and 60 mg ketamine IV solution administered orally in healthy male and female participants under fasting conditions.AnxietyMental Health - DepressionMental Health - AnxietyDepression
ACTRN12618001133224Zenith Technology Corporation Limited12
进行中(未招募)
1 期
A single-dose, randomized, two-period, two-sequence, crossover comparative bioavailability study on formulations containing ramipril, amlodipine and indapamide in combination product versus Triatec® 10 mg capsules (Sanofi - Produtos Farmacêuticos, Lda., Portugal), containing ramipril, Norvasc® 10 mg, tablets (Upjohn EESV, the Netherlands), containing amlodipine and Natrilix® 2.5 mg film-coated tablets (Les Laboratoires Servier, France), containing indapamide co-administered together as reference in healthy male and female volunteers under fasting conditions.hypertension
CTIS2024-514456-32-00Zaklady Farmaceutyczne Polpharma S.A.72
招募中
不适用
The pharmacokinetic characteristics and safety of Rap18001 in postmenopausal femaleDiseases of the musculo-skeletal system and connective tissue
KCT0004153Chonbuk National University Hospital6